Dongmei Wang, Ph.D.
With over 27 years of experience in pharmaceutical industry and CRO, Dr. Wang is currently the Executive Vice President, Global Project Management at Frontage Laboratories. In this position, Dongmei is also leading the effort to cross-sell Frontage’s comprehensive drug development services to clients across the globe.
Since she joined Frontage in Feb 2007, Dr. Wang has held several critical leadership roles including overseeing the US and China CMC operations. Previously as the EVP, Global Head of CMC Services, she was responsible for CMC (Chemistry Manufacturing & Control) including analytical services, formulation development, and manufacturing of GLP preclinical batches & GMP clinical trial materials. Under Dongmei’s leadership, the CMC team participated in numerous IND and ANDA programs for multiple clients.
Prior to joining Frontage, Dr. Wang served as the Director of Analytical Chemistry at NovaDel Pharma Inc. in New Jersey where her team contributed to the submission of several NDAs including two oral spray products which were approved by the FDA. Subsequently, Dongmei participated in the development of these two oral spray products including clinical supply manufacturing, CMC sections of 505(b)(2) filings, and technology transfer to commercial manufacturing sites. Prior to NovaDel Pharma, Dr. Wang headed Pharmaceutical Analysis and Control department at Therics Inc. in New Jersey, where she supported numerous 3D printing product development for 510(k) and IND filings.
Dr. Wang earned her Ph.D. in Chemistry from Iowa State University and performed postdoctoral research at the University of Chicago, Illinois. She received her MS in Chemical Engineering from China Institute of Atomic Energy and a BS degree in Chemistry from Peking University, China. Earlier in her career, Dr. Wang was a lecturer at the Graduate University of Chinese Academy of Science.
